Substantial support from "The Programme for Publicly-initiated Clinical Cancer Studies" to projects led by Mælandsmo, Loge and Myklebost
The Programme for Publicly-initiated Clinical Cancer Studies provides support to research projects that will increase understanding and thereby enhance the basis for effective decision-making within cancer treatment and care. The Research Council collaborates with the Norwegian Council for Quality Improvement and Priority Setting in Health Care on the selection of proposed topics for calls for proposals.
The program has recently decided to distribute a sum amounting to about 65 mill NOK among three projects, all of which are led by scientists from the Norwegian Radium Hospital, OUS: Gunhild Mælandsmo, Jon Håvard Loge and Ola Myklebost. This was celebrated on Friday April 13th (photo from the celebration under "More").
The 22 applications - totally applying for more than 290 mill NOK - were treated in two steps, first by an international panel of experts, evaluating scientific qualities of the projects. The results from this panel were considered by the program board in their evaluation of the quality of the applications as well as their relevance for the program and the announcement text.
The following three projects where granted support:
|Title of project:||Project leader:|
|Actionable Targets in Cancer Metastasis - from Bed to Bench to Byte to Bedside||Gunhild Mari Mælandsmo, Department of Tumor Biology, |
Institute for Cancer Research, Oslo University Hospital
|Late effects - early detection, follow-up and treatment||Jon Håvard Loge, National Resource Center for Late Effects after Cancer Treatment, Divison of Cancer Medicine, Surgery and Transplantation, Oslo Universitetssykehus|
|Personalized Cancer Medicine||Ola Myklebost, Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital|
People involved in the various projects:
Actionable Targets in Cancer Metastasis - from Bed to Bench to Byte to Bedside:
From Dept of Tumor Biology, Inst. for Cancer Res. (OUS): Anne Hansen Ree (50%), Kjersti Flatmark (50%), Gunhild Mælandsmo, Øystein Fodstad; Dept of Genetics, Inst. for Cancer Res. (OUS): Anne-Lise Børresen-Dale, from Dept. of Pathology (OUS): Vivi Ann Flørenes, Hege Russnes; from Dept. of Oncology (OUS): Kjetil Boye, Steinar Aamdal, Bjørn Naume; from Department of Gastoenterologic Surgery (OUS): Kjersti Flatmark (50%); from from the Interventional Centre (OUS): Bjørn Edwin; from UiO: Ole Christian Lingjærde. In addition, the following scientist from AHUS are involved: Vessela Kristensen, Anne Hansen Ree (50%) and Jürgen Geisler.
Personalized Cancer Medicine:
From the Dept of Tumor Biology, Inst. for Cancer Res. (OUS): Ola Myklebost, Eivind Hovig, Leonardo Meza-Zepeda, various other departments at OUS: Ragnhild A Lothe, Harald B Holte, Karol Axcrona, Bjørn Atle Bjørnbeth, Øyvind Bruland, Håvard E. Danielsen, Jørn E. Jacobsen, Arild Nesbakken, Rolf I. Skotheim, Erlend Smeland, Geir E. Tjønnfjord, Steinar Aamdal. In addition, this national projectet has partnes in Trondheim and Bergen
Late effects - early detection, follow-up and treatment
From Dept of Oncology: Jon Håvard Loge, From Department of Pediatric Medicine: Ellen Ruud; Dept of Oncology: Cecilie E Kiserud, Alv A Dahl, Alexander Fosså, Harald Holte, Kristin Valborg Reinertsen, Bjørn Naume, Olav Engebråten, Tone Ikdahl, Lene Thorsen, Sophie D Fosså; Dept of Cardiology: Svend Aakhus; Research Institute for Internal Medicine: Bente Halvorsen, Pål Aukrust; Dept of Genetics: Hege Edvardsen; from UiO: Arnstein Finset. Additional collaborators from Bergen, Trondheim, Tromsø and Denmark
About "The Programme for Publicly-initiated Clinical Cancer Studies (2011-2015)"
Offentlig initierte kliniske studier på kreftområdet: Søknadsresultater fra søknadsfrist 30.11.2011 (from the web pages of the Norwegian Research Council)
More about the "Personalized Cancer Medicine" project: led by Ola Myklebost here: cancergenomics.no
Time for celebration:
The generous financial support was duly celebrated with cream cake and champagne by the groups affiliated to the Department of Tumor Biology during the lunch break on Friday April 13th in the lobby of the magnificent new research building housing the Institute for Cancer Research.
|From left: Leonardo Meza-Zepeda, Anne Hansen Ree, Kjersti Flatmark, Gunhild Mari Mælandsmo, Eivind Hovig and Ola Myklebost. (click to enlarge)|